The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Tumor‐Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel‐Enhanced Immunotherapy with Polarization toward M1‐Type Macrophages on Triple Negative Breast Cancers
Abstract
Cancer immunotherapy has achieved promising clinical responses in recent years owing to the potential of controlling metastatic disease. However, there is a limited research to prove the superior therapeutic efficacy of immunotherapy on breast cancer compared with melanoma and non‐small‐cell lung cancer because of its limited expression of PD‐L1, low infiltration of cytotoxic T lymphocytes (CTLs), and high level of myeloid‐derived suppressor cells (MDSCs). Herein, a multifunctional nanoplatform (FA‐CuS/DTX@PEI‐PpIX‐CpG nanocomposites, denoted as FA‐CD@PP‐CpG) for synergistic phototherapy (photodynamic therapy (PDT), photothermal therapy (PTT) included) and docetaxel (DTX)‐enhanced immunotherapy is successfully developed. The nanocomposites exhibit excellent PDT efficacy and photothermal conversion capability under 650 and 808 nm irradiation, respectively. More significantly, FA‐CD@PP‐CpG with no obvious side effects can remarkably inhibit the tumor growth in vivo based on a 4T1‐tumor‐bearing mice modal. A low dosage of loaded DTX in FA‐CD@PP‐CpG can promote infiltration of CTLs to improve efficacy of anti‐PD‐L1 antibody (aPD‐L1), suppress MDSCs, and effectively polarize MDSCs toward M1 phenotype to reduce tumor burden, further to enhance the antitumor efficacy. Taken together, FA‐CD@PP‐CpG nanocomposites offer an efficient synergistic therapeutic modality in docetaxel‐enhanced immunotherapy for clinical application of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Nanoparticles in Photodynamic Therapy
Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,980
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Self-citationAlsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 774
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
Hossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Vollmer, J., & Krieg, A. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.12.008 · Cited by 585
Liu, J., Zheng, X., Yan, L., Zhou, L., Tian, G., Yin, W., Wang, L., Liu, Y., Hu, Z., Gu, Z., et al. (2015) · ACS Nano · doi:10.1021/nn506137n · Cited by 557
Self-citationNanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., et al. (2017) · Advanced Materials · doi:10.1002/adma.201703969 · Cited by 501
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 356
Umemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G.-F., Okada, M., Balazs, M., Adany, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 346
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Tian, Y., Jiang, X., Chen, X., Shao, Z., & Yang, W. (2014) · Advanced Materials · doi:10.1002/adma.201403562 · Cited by 258
Zhang, H., Jiang, W., Liu, R., Zhang, J., Zhang, D., Li, Z., & Luan, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b05142 · Cited by 253
Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 246
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice
Mundy-Bosse, B. L., Lesinski, G. B., Jaime-Ramirez, A. C., Benninger, K., Khan, M., Kuppusamy, P., Guenterberg, K., Kondadasula, S. V., Chaudhury, A. R., La Perle, K. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189
Feng, G., Fang, Y., Liu, J., Geng, J., Ding, D., & Liu, B. (2017) · Small · doi:10.1002/smll.201602807 · Cited by 179
Self-citationCuS@MOF-Based Well-Designed Quercetin Delivery System for Chemo–Photothermal Therapy
Jiang, W., Zhang, H., Wu, J., Zhai, G., Li, Z., Luan, Y., & Garg, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b13487 · Cited by 178
Stagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 166
Shi, H., Yan, R., Wu, L., Sun, Y., Liu, S., Zhou, Z., He, J., & Ye, D. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.03.035 · Cited by 145
Qian, D. Z., Rademacher, B. L. S., Pittsenbarger, J., Huang, C., Myrthue, A., Higano, C. S., Garzotto, M. G., Nelson, P. S., & Beer, T. M. (2009) · The Prostate · doi:10.1002/pros.21077 · Cited by 114
Zhao, Z., Shi, S., Huang, Y., Tang, S., & Chen, X. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am501608c · Cited by 106
Self-citationCancer-fighting viruses win approval
Ledford, H. K. (2015) · Nature · doi:10.1038/526622a · Cited by 101
“Minimalist” Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy
Wang, K., Wen, S., He, L., Li, A., Li, Y., Dong, H., Li, W., Ren, T., Shi, D., & Li, Y. (2018) · ACS Nano · doi:10.1021/acsnano.8b00558 · Cited by 96
Guo, W., Qiu, Z., Guo, C., Ding, D., Li, T., Wang, F., Sun, J., Zheng, N., & Liu, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15703 · Cited by 90
Docetaxel promotes the generation of anti-tumorigenic human macrophages
Millrud, C. R., Mehmeti, M., & Leandersson, K. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.018 · Cited by 62
Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives
Safari, E., Ghorghanlu, S., Ahmadi‐khiavi, H., Mehranfar, S., Rezaei, R., & Motallebnezhad, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27923 · Cited by 40
Distribution and prognostic value of tumor‑infiltrating T cells in breast cancer
Meng, S., Li, L., Zhou, M., Jiang, W., Niu, H., & Yang, K. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9460 · Cited by 38
Haggerty, T. J., Dunn, I. S., Rose, L. B., Newton, E. E., Martin, S., Riley, J. L., & Kurnick, J. T. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0926-x · Cited by 36
Fleisher, B., & Ait‐Oudhia, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s153056 · Cited by 14
Marmarelis, M. E., Davis, M., Sethi, N. S., Krajewksi, K. M., McKay, R. R., Choueiri, T. K., & Ott, P. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0129-x · Cited by 12
Cited by
Recent progress in nanomedicine for enhanced cancer chemotherapy
Wei, G., Wang, Y., Yang, G., Wang, Y., & Ju, R. (2021) · Theranostics · doi:10.7150/thno.57828 · Cited by 463
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
Metadata
- Authors
- Chen, L., Zhou, L., Wang, C., Han, Y., Lu, Y., Liu, J., Hu, X., Yao, T., Lin, Y., Liang, S., Shi, S., & Dong, C.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-11-13
- Volume
- 31
- Issue
- 52
- Pages
- e1904997-e1904997
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2983982331
- Cited by
- 337
- References
- 46
- FWCI
- 15.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.